Single-dose AQ001S PK Study in Healthy Volunteers (BORA)

A Randomized, Open Label, Single-center, Single-dose, Four-period Crossover Clinical Trial to Assess the PK Profile and Safety of Budesonide Inhalation Solution AQ001S Compared to Budesonide Inhalation Suspension in Healthy Volunteers

This is a randomized, open label, single-center, single-dose, four-period crossover clinical study to assess the pharmacokinetic profile and safety of a budesonide inhalation solution (AQ001S) compared to a budesonide inhalation suspension (comparator) in healthy volunteers.

Study Overview

• Status: Completed
• Conditions: Pharmacokinetics
• Intervention / Treatment: Drug: Budesonide Inhalant Product

Detailed Description

This is a randomized, open label, single-center, single-dose, four-period crossover clinical study to assess the pharmacokinetic profile and safety of a budesonide inhalation solution (AQ001S) compared to a budesonide inhalation suspension (comparator) in healthy volunteers. Three (3) different AQ001S concentrations (i.e. 0.125 mg/2 mL, 0.250 mg/2mL and 0.500 mg/2 mL) will be compared to budesonide inhalation suspension 1.0 mg/2 ml.

Twenty (20) male and female healthy volunteers, from 18 to 60 years old, must complete the study. The study drug will be administered by nebulization.

The primary PK objective is to characterize the pharmacokinetic (PK) profile of AQ001S inhalation solution.

The primary safety objective is to assess the safety of AQ001S inhalation solution.

• Study Type: Interventional
• Enrollment (Actual): 29
• Phase: Phase 1

Contacts and Locations

Study Locations

• Bulgaria
  • Sofia, Bulgaria, 1612
    • MC Comac Medical Ltd.

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 16 years to 58 years (Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

1. Subjects who have given written informed consent.
2. Healthy volunteers of both genders, aged ≥ 18 and ≤ 60 years.
3. Subjects with body weight > 45 kg and Body Mass Index ≥ 18.5 and ≤ 24.9kg/m2.
4. Healthy volunteers are declared healthy based on medical history, physical examination, electrocardiogram, pulmonary function test (Forced Expiratory Volume in 1 second ≥ 80% of the predicted normal value and Forced Expiratory Volume in 1 second/ Forced Vital Capacity ≥ 70%).
5. Clinical laboratory values within the laboratory stated normal range; if not within this range, they must be without any clinical significance according to the Investigator.
6. Subjects who never smoked.
7. Women of childbearing potential (WOCBP) may be enrolled if they practice a method of birth control with a reliability of at least 90% and agree to continue doing so throughout the treatment period (e.g. condom, intrauterine device or hormonal contraception).
8. Any female subject with childbearing potential has a negative pregnancy test at Screening visit and prior to dosing at each treatment period.
9. Reliable subjects who are willing to be available for the duration of the clinical study and willing to comply with clinical study procedures.
10. Subjects who have the ability to understand the requirements of the clinical study.

Exclusion Criteria:

1. Any clinically important abnormality identified at the screening medical assessment (physical examination/medical history) or clinically relevant laboratory abnormalities.
2. Clinically significant history or presence of pulmonary malformations, chronic bronchitis, asthma, emphysema, cystic fibrosis or any other pulmonary disease
3. History or presence of pulmonary tuberculosis.
4. Viral or bacterial upper or lower respiratory tract infection, or sinus or middle ear infection, within 4 weeks prior to the screening visit.
5. Untreated oral candidiasis.
6. History or presence of prolonged QTc interval (> 450 ms), or any other clinically significant electrocardiogram abnormalities as judged by the Investigator based on 12-lead electrocardiogram recordings at Screening Visit.
7. History or presence of malignancy of any system organ class (other than localized basal cell carcinoma of the skin), treated or untreated, within the past 5 years prior to Screening Visit, regardless of whether there is no evidence of local recurrence or metastases.
8. Eye disorders, especially glaucoma, or a family history of glaucoma.
9. History of alcohol or drug abuse.
10. Inability to abstain from alcohol consumption for the duration of study period.
11. Immunosuppressive treatment, including topical and systemic corticosteroids (e.g., oral, parenteral, ocular, nasal or inhaled), within 4 weeks before Screening Visit.
12. Use of prescription or non-prescription drugs, except for simple analgesics (e.g. paracetamol) and hormonal contraception for women, including vitamins, herbal and dietary supplements (including St John's Wort [Hypericum]) within 7 days (or 2 weeks if the drug is a potential enzyme inducer) or 5 half-lives (whichever is longer) before the Screening Visit.
13. Pregnant or breastfeeding female subjects.
14. History of hypersensitivity or existing contraindication to budesonide or any other study medication ingredients.
15. Blood or plasma donation within 4 weeks prior to Screening Visit.
16. Any surgical or medical condition which might significantly alter the absorption, distribution, metabolism, or excretion of drugs, or which may jeopardize the subject in case of participation in the clinical study.
17. History or presence of any other clinically relevant disease of any major system organ class (e.g. cardiovascular, pulmonary, renal, hepatic, gastrointestinal, reproductive, endocrinological including any type of Diabetes mellitus, neurological, psychiatric or orthopedic disease) as judged by the Investigator.
18. COVID-19, Hepatitis B and C and HIV positive tests
19. Any COVID-19 vaccine within 2 weeks prior to the first dose of study drugs, and during the entire study participation including 2 weeks after the last dose of study drug.
20. Subjects who participated in an investigational study within the 12 weeks prior to the start of the study

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Crossover Assignment
• Masking: None (Open Label)

Number of Arms

4

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: AQ001S 0.125 mg/2mL single-dose; AQ001S 0.125 mg/2 ml (budesonide 0.125 mg/2 ml inhalation solution) single-dose administered by nebulization.	Drug: Budesonide Inhalant Product; Single-dose of budesonide solution administered by nebulization.; Other Names: Budesonide solution administered by nebulization
Experimental: AQ001S 0.250 mg/2mL single-dose; AQ001S 0.250 mg/2 ml (budesonide 0.250 mg/2 ml inhalation solution) single-dose administered by nebulization.	Drug: Budesonide Inhalant Product; Single-dose of budesonide solution administered by nebulization.; Other Names: Budesonide solution administered by nebulization
Experimental: AQ001S 0.500 mg/2mL single-dose; AQ001S 0.500 mg/2 ml (budesonide 0.500 mg/2 ml inhalation solution) single-dose administered by nebulization.	Drug: Budesonide Inhalant Product; Single-dose of budesonide solution administered by nebulization.; Other Names: Budesonide solution administered by nebulization
Active Comparator: Budesonide inhalation suspension 1.0 mg/2 ml single-dose; Pulmicort Respules® 1.0 mg/2 ml is a budesonide inhalation suspension administered by nebulization.	Drug: Budesonide Inhalant Product; Single-dose of budesonide solution administered by nebulization.; Other Names: Budesonide solution administered by nebulization

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Assessment of pharmacokinetics (Cmax) of budesonide through analysis of blood samples	Blood samples will be collected from each subject using an indwelling intravenous catheter. In total 17 blood samples for PK assessments over 24 hours will be collected.	Day 1 (predose) and at 2', 5', 10', 15', 20', 30', 45', 60', 90', 120', 180', 240', 360', 10h, 18h and 24h postdose
Assessment of pharmacokinetics (Tmax) of budesonide through analysis of blood samples	Blood samples will be collected from each subject using an indwelling intravenous catheter. In total 17 blood samples for PK assessments over 24 hours will be collected.	Day 1 (predose) and at 2', 5', 10', 15', 20', 30', 45', 60', 90', 120', 180', 240', 360', 10h, 18h and 24h postdose
Assessment of pharmacokinetics (AUC) of budesonide through analysis of blood samples	Blood samples will be collected from each subject using an indwelling intravenous catheter. In total 17 blood samples for PK assessments over 24 hours will be collected.	Day 1 (predose) and at 2', 5', 10', 15', 20', 30', 45', 60', 90', 120', 180', 240', 360', 10h, 18h and 24h postdose
Assessment of the safety through to incidence of Adverse Events of AQ001S inhalation solution	Incidence of treatment-related adverse events (AE), including acute bronchospasm	From baseline up to 17 days after first study drug intake
Assessment of the general tolerability through to vital signs (blood pressure: systolic and diastolic blood pressure) of AQ001S inhalation solution	Vital signs assessment through blood pressure (systolic and diastolic blood pressure)	From baseline up to 17 days after first study drug intake
Assessment of the general tolerability through to vital signs (pulse rate) of AQ001S inhalation solution	Vital signs assessment through pulse rate	From baseline up to 17 days after first study drug intake
Assessment of the general tolerability through to vital signs (respiratory rate) of AQ001S inhalation solution	Vital signs assessment through respiratory rate	From baseline up to 17 days after first study drug intake
Assessment of the general tolerability through to ECG (PR interval duration)	ECG assessment through to PR interval duration	From baseline up to 17 days after first study drug intake
Assessment of the general tolerability through to ECG (heart rhythm) of AQ001S inhalation solution	ECG assessment through to heart rhythm	From baseline up to 17 days after first study drug intake
Assessment of the general tolerability through to ECG (QRS interval duration) of AQ001S inhalation solution	ECG assessment through to QRS interval duration	From baseline up to 17 days after first study drug intake
Assessment of the general tolerability through to ECG (Corrected QT interval (QTc)) of AQ001S inhalation solution	ECG assessment through to Corrected QT interval	From baseline up to 17 days after first study drug intake
Assessment of the general tolerability through to ECG (QT interval duration) of AQ001S inhalation solution	ECG assessment through to QT interval duration	From baseline up to 17 days after first study drug intake
Assessment of the general tolerability through to physical examination	General tolerability through the rate of patients with observed abnormalities in the following organic systems: general appearance, head and neck (incl. oropharyngeal examination), skin, respiratory system, cardiovascular system, abdomen, urogenital system, nervous system, ear, eyes and nose, musculoskeletal system	From baseline up to 17 days after first study drug intake
Assessment of the local tolerability through to increased bronchial irritability of AQ001S inhalation solution	Incidence of Increased bronchial irritability	From baseline up to 17 days after first study drug intake
Assessment of the local tolerability through to paradoxical bronchospasm of AQ001S inhalation solution	Incidence of paradoxical bronchospasm	From baseline up to 17 days after first study drug intake
Assessment of the local tolerability through to oropharyngeal examination ((e.g. vocal cord myopathy, fungal infection) of AQ001S inhalation solution	Incidence of oropharyngeal examination ((e.g. vocal cord myopathy, fungal infection)	From baseline up to 17 days after first study drug intake

Collaborators and Investigators

• Sponsor: Aquilon Pharmaceuticals S.A.
• Investigators: Principal Investigator: Dobrin Svinarov, MD, MC Comac Medical Ltd.

Study record dates

Study Major Dates

• Study Start (Actual): November 12, 2021
• Primary Completion (Actual): December 24, 2021
• Study Completion (Actual): February 21, 2022

Study Registration Dates

• First Submitted: November 2, 2021
• First Submitted That Met QC Criteria: November 24, 2021
• First Posted (Actual): December 8, 2021

Study Record Updates

• Last Update Posted (Actual): November 3, 2022
• Last Update Submitted That Met QC Criteria: November 2, 2022
• Last Verified: November 1, 2021

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Physiological Effects of Drugs; Autonomic Agents; Peripheral Nervous System Agents; Anti-Inflammatory Agents; Glucocorticoids; Hormones; Hormones, Hormone Substitutes, and Hormone Antagonists; Bronchodilator Agents; Anti-Asthmatic Agents; Respiratory System Agents; Budesonide
• Other Study ID Numbers: BORA Study

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: Yes
• IPD Plan Description: Individual participant data that underlie the results reported in this article, after deidentification (text, tables, figures, and appendices).
• IPD Sharing Time Frame: Beginning 6 months and ending 5 years following article publication.
• IPD Sharing Access Criteria: To Investigators whose proposed use of the data has been approved by sponsor.
• IPD Sharing Supporting Information Type: Study Protocol; Clinical Study Report (CSR)

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No